Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Tidal Investments LLC

Tidal Investments LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 37.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,452 shares of the medical research company’s stock after acquiring an additional 2,319 shares during the period. Tidal Investments LLC’s holdings in Charles River Laboratories International were worth $1,665,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CRL. Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the third quarter worth approximately $59,000. Virtu Financial LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth approximately $601,000. Toronto Dominion Bank boosted its position in shares of Charles River Laboratories International by 1.6% during the third quarter. Toronto Dominion Bank now owns 25,617 shares of the medical research company’s stock worth $5,046,000 after buying an additional 397 shares during the period. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the third quarter worth approximately $966,000. Finally, Gould Capital LLC acquired a new stake in Charles River Laboratories International in the third quarter worth approximately $1,225,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CRL. UBS Group upped their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. TD Cowen upped their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Robert W. Baird dropped their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. Finally, Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $214.00.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $189.39 on Wednesday. The company’s fifty day moving average is $194.42 and its two-hundred day moving average is $202.68. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00. The company has a market cap of $9.68 billion, a P/E ratio of 23.70, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the business posted $2.72 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).